CLINTON ADMINISTRATION OBJECTIVE IS NOT PRICE CONTROLS BUT COST CONTAINMENT, GORE ADVISOR SAYS; BIO's NEXT FOCUS ON EMERGING COMPANIES AND PUBLIC PERCEPTIONS
The Clinton Administration supports "cost containment, not cost control" for new therapies arriving on the market, Vice President Gore's chief domestic policy advisor Gregory Simon told representatives from the biotechnology industry on May 24 during a keynote speech at the Biotechnology Industry Organization's annual meeting in Toronto.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth